Sunesis Pharmaceuticals, Inc. (SNSS) is a Major Pharmaceuticals company listed on NASDAQ. There were no new wire items for SNSS in the last 30 days. The most recent was published Mar 11, 2021.
Latest news
25 items- 13D/GSEC Form SC 13D/A filedSC 13D/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
- 13D/GSEC Form SC 13G filedSC 13G - Viracta Therapeutics, Inc. (0001061027) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - Viracta Therapeutics, Inc. (0001061027) (Subject)
- INSIDERSEC Form 3 filed by J. Barry Simon3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by Stephen Rubino3 - Viracta Therapeutics, Inc. (0001061027) (Issuer)
- SECSEC Form 8-K filed8-K - Viracta Therapeutics, Inc. (0001061027) (Filer)
- 13D/GSEC Form SC 13D filedSC 13D - SUNESIS PHARMACEUTICALS INC (0001061027) (Subject)
- ANALYSTSunesis Pharmaceuticals upgraded by Oppenheimer with a new price targetOppenheimer upgraded Sunesis Pharmaceuticals from Market Perform to Outperform and set a new price target of $12.00
- INSIDERSEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3: Gur Roshwalb claimed ownership of 7,392,237 units of Common Stock3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3: R. Daniel Chevallard claimed ownership of 44,760 units of Common Stock3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by E Thomas Darcy3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by Michael Huang3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by Lafayette Samuel Murphy3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by Roger Pomerantz3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3 filed by Lisa Rojkjaer3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- INSIDERSEC Form 3: Ivor Royston claimed ownership of 559,198 units of Common Stock3 - SUNESIS PHARMACEUTICALS INC (0001061027) (Issuer)
- SECSEC Form 8-K filed8-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)
- SECSEC Form 10-K filed10-K - SUNESIS PHARMACEUTICALS INC (0001061027) (Filer)
- ANALYSTSunesis Pharmaceuticals upgraded by Oppenheimer with a new price targetOppenheimer upgraded Sunesis Pharmaceuticals from Perform to Outperform and set a new price target of $12.00
- SECSEC Form 425 filed425 - SUNESIS PHARMACEUTICALS INC (0001061027) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - SUNESIS PHARMACEUTICALS INC (0001061027) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - SUNESIS PHARMACEUTICALS INC (0001061027) (Subject)
- 13D/GSEC Form SC 13G/A filedSC 13G/A - SUNESIS PHARMACEUTICALS INC (0001061027) (Subject)
- PRViracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated LymphomaSAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea
SNSS FAQ
6 questionsWhat is the latest news on SNSS?
Quantisnow has not tracked any new filings, ratings or press releases for SNSS in the last 30 days. The most recent wire item was published on March 11, 2021.Where does SNSS stock trade?
Sunesis Pharmaceuticals, Inc. (SNSS) is listed on NASDAQ.What sector and industry is SNSS in?
Sunesis Pharmaceuticals, Inc. operates in the Health Care sector, Major Pharmaceuticals industry.When did Sunesis Pharmaceuticals, Inc. go public?
Sunesis Pharmaceuticals, Inc. (SNSS) completed its IPO in 2005.What companies are similar to SNSS?
Notable peers in the same industry include ADMS (Adamas Pharmaceuticals, Inc.), ADRO (Aduro Biotech, Inc.), ADXS (Advaxis, Inc.), ARPO (Aerpio Pharmaceuticals, Inc.), AIMT (Aimmune Therapeutics, Inc.). Compare SNSS side-by-side with any of them on Quantisnow.How can I track SNSS on Quantisnow?
Quantisnow aggregates Sunesis Pharmaceuticals, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNSS to receive live email and push alerts on every new disclosure.